Product Overview: Valcivir
Valcivir 500 mg is an antiviral pharmaceutical compound manufactured by Cipla, containing valacyclovir hydrochloride as the active ingredient. This nucleoside analogue prodrug undergoes enzymatic conversion to acyclovir in cellular systems, making it valuable for in-vitro viral replication studies. Researchers at Stroid UK Shop investigate valacyclovir’s mechanism of action in herpes simplex virus, varicella-zoster virus, and cytomegalovirus research protocols. The compound demonstrates enhanced bioavailability compared to acyclovir in pharmacokinetic studies, providing researchers with a potent tool for examining antiviral resistance patterns and viral DNA polymerase inhibition mechanisms.
Pharmaceutical Research Applications
Laboratory investigations utilise Valcivir to examine viral thymidine kinase phosphorylation pathways and DNA chain termination events in infected cell cultures. Research teams study the compound’s selective uptake by virally-infected cells versus healthy tissue in comparative analysis protocols. The valacyclovir molecule provides researchers access to broader antiviral spectrum studies, particularly in examining prophylactic treatment models and viral load reduction mechanisms. Scientists working with other pharmaceutical compounds often integrate valacyclovir studies alongside SARM research available through specialised categories and peptide investigations from dedicated research collections to examine comprehensive cellular response patterns in laboratory settings.
Technical Specifications
| Property | Value |
|---|---|
| Active Ingredient | Valacyclovir Hydrochloride |
| Strength | 500 mg per tablet |
| Manufacturer | Cipla Limited |
| Molecular Formula | C₁₃H₂₀N₆O₄·HCl |
| CAS Number | 124832-26-4 |
| Storage Conditions | Room temperature, dry environment |
| Research Classification | Antiviral nucleoside analogue |
Laboratory Compliance
Valcivir 500 mg tablets are supplied exclusively for in-vitro research applications in accredited laboratory environments. This pharmaceutical-grade compound requires appropriate handling protocols and should only be utilised by qualified research personnel in controlled experimental settings. Researchers must maintain proper documentation of investigational procedures and ensure compliance with institutional research guidelines. All studies involving this antiviral compound should follow established laboratory safety protocols for pharmaceutical research materials. This product is not intended for human consumption or therapeutic use outside of approved laboratory research contexts.
